Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths
Although nearly 10% of Americans suffer from a rare disease, clinical progress in individual rare diseases is severely compromised by lack of attention and research resources compared to common diseases. It is thus imperative to investigate these diseases at their most basic level to build a foundat...
Saved in:
Main Authors: | Peter A. Kropp (Author), Rosemary Bauer (Author), Isabella Zafra (Author), Carina Graham (Author), Andy Golden (Author) |
---|---|
Format: | Book |
Published: |
The Company of Biologists,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug discovery: Insights from the invertebrate Caenorhabditis elegans
by: Sebastián Giunti, et al.
Published: (2021) -
Identification of genetic suppressors for a BSCL2 lipodystrophy pathogenic variant in Caenorhabditis elegans
by: Xiaofei Bai, et al.
Published: (2024) -
Modeling neurodegeneration in Caenorhabditis elegans
by: Kim A. Caldwell, et al.
Published: (2020) -
Mechanisms of iron metabolism in Caenorhabditis elegans
by: Elizabeth A Leibold, et al.
Published: (2014) -
Caenorhabditis elegans for research on cancer hallmarks
by: Julián Cerón
Published: (2023)